Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Buys $108,752.21 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Ramiro Guerrero purchased 78,239 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $108,752.21. Following the completion of the acquisition, the director owned 689,081 shares in the company, valued at $957,822.59. This represents a 12.81% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Ramiro Guerrero also recently made the following trade(s):

• On Friday, August 28th, Ramiro Guerrero purchased 46,620 shares of MAIA Biotechnology stock. The stock was acquired at an average price of $1.35 per share, with a total value of $62,937.00.
• On Wednesday, August 26th, Ramiro Guerrero acquired 8,931 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.39 per share, with a total value of $12,414.09.
• On Monday, August 24th, Ramiro Guerrero acquired 1,794 shares of MAIA Biotechnology stock. The shares were bought at an average cost of $1.33 per share, with a total value of $2,386.02.
• On Thursday, August 20th, Ramiro Guerrero acquired 11,899 shares of MAIA Biotechnology stock. The shares were bought at an average price of $1.37 per share, for a total transaction of $16,301.63.

MAIA Biotechnology Stock Performance

MAIA stock opened at $1.33 on Friday. MAIA Biotechnology, Inc. has a one year low of $0.87 and a one year high of $3.19. The company’s fifty day moving average price is $1.37 and its 200-day moving average price is $1.43. The company has a market capitalization of $80.90 million, a PE ratio of -2.15 and a beta of 0.25.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, research analysts predict that MAIA Biotechnology, Inc. will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology during the 2nd quarter valued at approximately $52,000. PVG Asset Management Corp bought a new position in shares of MAIA Biotechnology during the 1st quarter valued at approximately $46,000. Susquehanna International Group LLP bought a new position in shares of MAIA Biotechnology during the 2nd quarter valued at approximately $51,000. Finally, Corsair Capital Management L.P. purchased a new position in shares of MAIA Biotechnology in the first quarter valued at $140,000. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.